Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE: Niraparib + Anti-PD-L1 Maintenance in SLFN11-positive ED-SCLC
NCT05718323Phase 2Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of niraparib in small cell lung cancer (SCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-Free Survival rate at 3 months. Started Dec 2023; status: recruiting.
02
Drugs
niraparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05718323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718323.